Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability

NCT06291038 | Recruiting

• 1 other identifier: 2021/0381/HP
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 4

Brief Summary

Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high. One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test. Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D). The working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.

Conditions

Irritable Bowel Syndrome

Outcome Measures

Primary Outcomes (1)

• Evaluate the symptomatic effectiveness of glutamine supplementation in patients suffering from IBS-D with increased intestinal permeability

  the change in Francis score measured before and after glutamine or placebo supplementation for 8 weeks in patients suffering from IBS-D with increased intestinal permeability. Rated from 0 et 500, 500 is the worst case with a severe form

  8 weeks

Study Arms (2)

Glutamine

EXPERIMENTAL

• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks.

Dietary Supplement: • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks

Protifar

PLACEBO COMPARATOR

• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

Dietary Supplement: • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

Interventions

• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks. DIETARY_SUPPLEMENT

treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

Protifar

• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks DIETARY_SUPPLEMENT

treatment with glutamine at a dose of 5g 3 times a day for 8 weeks

Glutamine

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult aged 18 to 75
• Diarrheal irritable bowel syndrome (IBS-D), according to the Rome IV criteria (appendix 2)
• Treatments for IBS stable for \>1 month
• Affiliation to a social security system
• Adult person having read and understood the information letter and signed the consent form
• Woman of childbearing age having effective/very effective contraception (Cf. CTFG) (estrogen-progestins or intrauterine device or tubal ligation) for 1 month and a negative urine pregnancy test

You may not qualify if:

• Taking probiotics, anti-inflammatories, corticosteroids or antibiotics systemically (oral or injectable) in the month preceding the study and during the duration of the study treatment,
• Known diagnosis of active autoimmune disease (type 1 diabetes, lupus, multiple sclerosis, thyroiditis, ankylosing spondylitis, rheumatoid arthritis or psoriasis)
• Known allergy to glutamine,
• Contraindication to taking glutamine, protein powder, lactulose or mannitol (including sugar-free chewing gum),
• Use of osmotic laxatives and/or taking lactulose and/or protein supplementation (including taking glutamine) in the 4 weeks preceding the start of the study,
• Renal insufficiency (GFR\<40mL/min), hepatic insufficiency (PT\<70) or known heart disease,
• ATCD of digestive disease (celiac disease, chronic inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy),
• Occlusive or subocclusive syndrome,
• Digestive perforation or suspicion of perforation,
• Abdominal pain syndrome of undetermined cause,
• Chronic alcohol consumption (\>14 units/week),
• Pregnant or parturient or breastfeeding woman or proven absence of contraception,
• Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship,
• Person participating in research participating in another trial / having participated in another trial within 2 weeks,
• History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent.

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (4)

Chu Amiens

Amiens, 80054, France

NOT YET RECRUITING

CHU CAEN

Caen, 14033, France

RECRUITING

Ch Le Havre

Le Havre, 76290, France

RECRUITING

Chu Rouen

Rouen, 76031, France

RECRUITING

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: double blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Multicentric; prospective; randomized; double blind; interregional

Study Record Dates

• First Submitted: February 26, 2024
• First Posted: March 4, 2024
• Study Start: October 3, 2024
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2029
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (4)